Related Experiment Video

Updated: May 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K

Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents

Yann-Alexandre Vano1, Eric Tartour, Laure S Fournier

  • 1Department of Medical Oncology, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Descartes University, Paris, France.

Expert Review of Anticancer Therapy
|March 20, 2014
PubMed

Insights

Targeted therapies have revolutionized metastatic renal cell carcinoma (mRCC) treatment, improving survival. This review focuses on identifying prognostic and predictive biomarkers for VEGF-targeted agents in advanced clear cell RCC.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has advanced significantly with targeted therapies.
  • Vascular Endothelial Growth Factor (VEGF)-targeted drugs and PI3K/AKT/mTOR pathway inhibitors have become standard treatments.
  • Median survival for mRCC patients receiving first-line targeted therapy now exceeds two years.

Purpose of the Study:

  • To review recent research on prognostic and predictive biomarkers for advanced clear cell RCC.
  • To identify factors that predict response to VEGF-targeted therapy in mRCC patients.

Main Methods:

  • Literature review of recent key studies.
  • Focus on prognostic and predictive factors in advanced clear cell RCC.
  • Analysis of VEGF-targeted agents' efficacy.

Main Results:

  • Significant progress has been made in identifying prognostic factors for mRCC.
  • The identification of predictive biomarkers for targeted therapy remains a critical challenge.
  • VEGF-targeted agents have shown improved survival outcomes.

Conclusions:

  • Further research into biomarkers is crucial for optimizing targeted therapy in mRCC.
  • Predictive biomarkers are essential for personalizing treatment strategies.
  • Understanding these factors will improve patient outcomes in advanced clear cell RCC.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

120
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K